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Abstract
Background and aim: Neutrophil-lymphocyte ratio (NLR) and lymphocyte-monocyte ratio (LMR) are associated
with clinical outcomes in malignancy, cardiovascular disease and stroke. Here we investigate their association with
outcome after acute ischaemic stroke treated by mechanical thrombectomy (MT).
Methods: Patients were selected using audit data for MT for acute anterior circulation ischaemic stroke at a UK
centre from May 2016–July 2017. Clinical and laboratory data including neutrophil, lymphocyte and monocyte
count tested before and 24 h after MT were collected. Poor functional outcome was defined as modified Rankin
Scale (mRS) of 3–6 at 3 months. Multivariable logistic regression analyses were performed to explore the
relationship of NLR and LMR with functional outcome.
Results: One hundred twenty-one patients (mean age 66.4 ± 16.7, 52% female) were included. Higher NLR
(adjusted OR 0.022, 95% CI, 0.009–0.34, p = 0.001) and lower LMR (adjusted OR − 0.093, 95% CI (− 0.175)−(− 0.012),
p = 0.025) at 24-h post-MT were significantly associated with poorer functional outcome when controlling for age,
baseline NIHSS score, infarct size, presence of good collateral supply, recanalisation and symptomatic intracranial
haemorrhage on multivariate logistic regression. Admission NLR or LMR were not significant predictors of mRS at 3
months. The optimal cut-off values of NLR and LMR at 24-h post-MT that best discriminated poor outcome were
5.5 (80% sensitivity and 60% specificity) and 2.0 (80% sensitivity and 50% specificity), respectively on receiver
operating characteristic curve analysis.
Conclusion: NLR and LMR tested at 24 h after ictus or intervention may predict 3-month functional outcome.
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Introduction
Inflammation has been increasingly recognised as a key
contributor to the pathophysiology of acute ischaemic
stroke (AIS) [1]. Elements of the immune system are
intimately involved in the initiation and propagation of is-
chaemic brain injury, and developing immunosuppression
secondary to cerebral ischaemia may possibly promote
intercurrent infections [1]. Neutrophil to lymphocyte ratio
(NLR) and lymphocyte to monocyte ratio (LMR) are
potential novel biomarkers of baseline inflammatory re-
sponse which have recently been reported as important
predictors of AIS morbidity and mortality [2–4].
Randomised controlled trials have demonstrated that
AIS treatment by mechanical endovascular therapy
(MT) in addition to intravenous (IV) recombinant tis-
sue plasminogen activator (rtPA) significantly improves
the outcomes of AIS with large vessel occlusion [5].
Less favourable responses to MT were associated with
advanced age, high baseline National Institutes of
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Health Stroke Scale (NIHSS) score, large infarct vol-
ume, recanalisation and poor cerebral collateral circula-
tion [6–8]. Similarly, there is growing evidence that
higher admission NLR may contribute to worse out-
come at 3-month post-AIS treated with IV rtPA and/or
MT [4, 9]. Conversely, lower lymphocyte to monocyte
ratio (LMR) was associated with a poor prognosis in
AIS including those treated with thrombolysis [10].
As part of auditing our thrombectomy outcomes,
we noted whether there was a correlation between
NLR and LMR and outcome in our cohort of AIS pa-
tients who underwent thrombectomy. We also investi-
gated whether there were dynamic changes in NLR
and LMR values and trends between NLR-stroke and
LMR-stroke correlations.
Methods
We performed a retrospective audit of consecutive, pro-
spectively collected, ischaemic stroke cases referred for
MT within a single regional, hyperacute stroke unit at St
George’s Hospital. This is the main referral centre for
MT in the UK, operating 24 h a day, 7 days a week. AIS
patients admitted from 1st May 2016–1st July 2017 were
used in the analysis. The patients’ data were entered in
an audit database. Patients were selected for this investi-
gation if they met all of the following criteria: adults (i.e.
older than 16 years) (1) with a clinically confirmed acute
anterior circulation ischaemic stroke with large vessel
occlusion (2) undergoing MT. Exclusion criteria consti-
tuted (1) clinically confirmed acute posterior circulation
ischaemic stroke; (2) patients with a history of terminal
Fig. 1 Dynamics of NLR (a) and LMR (b) from admission to 24 h after mechanical thrombectomy. An axis y figures reflects 95% confidence
interval (Cl) that is a range of values 95% certain contains the true mean of the NLR and LMR
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cancer, haematological disease, recent major trauma or
surgery, severe hepatic or renal disease determined by
clinical history or laboratory data; (3) immunosuppres-
sant use; (4) active infections within the 2 weeks prior to
admission.
Clinical data collected included demographics, vascu-
lar risk factors and admission baseline NIHSS score
(determined by an in-house neurologist). Treatment
parameters included IV rtPA administration and the
Modified Thrombolysis in Cerebral Infarction (mTICI)
grade (determined by an in-house interventional neuro-
radiologist: complete recanalisation classified as mTICI
score 2b or 3 [11]), computed tomography (CT) angiog-
raphy based cerebral collateral circulation [12] (good
defined as more than 50% of the middle cerebral artery
(MCA) territory vs poor) and stroke volume (< 1/3 MCA
territory, > 1/3 MCA territory and larger than the MCA
territory), anaesthetic mode (general anaesthesia vs local
or conscious sedation) and haemorrhagic conversion
based on the European Cooperative Acute Stroke Study
(ECASS) classification [13]. The Alteplase Thrombolysis
for Acute Noninterventional Therapy in Ischemic Stroke
(ATLANTIS)/CT Summit criteria [14–16] has defined ‘> 1/
3 MCA territory’ stroke volume as substantial involvement
of ≥ 2 of the following 4 areas: frontal, parietal, temporal, or
both basal ganglia and insula. Involvement of all 4 areas:
frontal, parietal, temporal, basal ganglia, insula and beyond
was defined as ‘beyond MCA territory’. All remaining scans
were categorised as < 1/3 MCA involvement. All neuroim-
aging ratings were done by a neurologist (DL, UK and
ACP). Outcome was measured by the modified Rankin
Scale (mRS) at 90 days during clinical follow-up by trained
staff. Poor outcome was defined as functional dependence
and mortality (mRS 3–6), whereas good outcome was
defined as an mRS score 2 or lower. Venous blood sam-
pling was obtained on admission and within 24 h post-MT.
Fig. 2 Correlation between LMR, NLR and infarct size based on The Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic
Stroke (ATLANTIS)/CT Summit criteria [14–16]
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Laboratory data included full blood count with white blood
cells differentials, urea and electrolytes, liver function tests
and C-reactive protein.
Statistical analysis was performed in SPSS (V.22; SPSS
Inc., Chicago, IL, USA). Depending on the normality of
distribution as assessed by the Kolmogorov-Smirnov
test, continuous variables were compared using the t test
for independent samples, or the Mann-Whitney U test.
Categorical variables were analysed as frequency and
percentage and differences among these variables were
assessed by the chi-square test. For univariate correl-
ation analysis, Spearman Rho was used. Logistic regres-
sion analysis was used to analyse the ability of NLR or
LMR to predict 90-day mRS alongside other variables.
The level of significance for these descriptive compari-
sons was established at 0.05 for two-sided hypothesis
testing. Receiver operating characteristic (ROC) curves
were used to test the overall discriminative ability of the
NLR or LMR for outcome and to establish optimal cut-
off points at which the sum of the specificity and sensi-
tivity was highest.
Results
A total of 121 patients met the criteria for inclusion and
subsequent analysis. The mean age of the patient cohort
was 66.4 years (SD ± 16.7) with 52% being female. Median
baseline NIHSS score was 19 (range 1–28). Median baseline
and 90-day mRS were 0 (IQR 4) and 3 (IQR 2), respectively.
Ninety-four patients (77.6%) received intravenous rtPA as
well. Complete recanalisation was achieved in 90 (74%) pa-
tients. Of the 25 (21%) patients with intracranial haemor-
rhage (ICH), 11 (9%) had symptomatic (sICH). Median
NLR at admission (a_NLR) was 2.4 (range 0.5–31.8); LMR
at admission (a_LMR) was 3.1 (range 0.6–8.6); 24-h NLR
(24h_NLR) was 6.2 (range 1–35) and 24-h LMR (24h_
LMR) was 1.7 (range 0.3–5).
Dynamic change and association between NLR and LMR
An increasing trend in the NLR (Fig. 1a) and decreas-
ing trend in the LMR (Fig. 1b) was observed after 24-h
post-MT, and there was correlation between admis-
sion NLR and LMR (r = − 7.47, p < 0.0001) and NLR
and LMR 24 h after MT (r = − 6.69, p < 0.0001), re-
spectively (Additional file 2: Figure S1 A and B).
Seventy-five percent cases had the combined rising
NLR and falling LMR trend (the remaining 25% included
those with unchanging NLR, rising NLR and LMR, or
missing values). There was no significant association of a
dynamic change in NLR or LMR and whether recanali-
sation was achieved. Eighty-three percent (101/121) of
stroke patients with complete recanalisation had a rising
NLR compared with 74% (23/31) of stroke patients with
incomplete or no recanalisation (χ2 = 1.41; p = 0.23).
Eighty-one percent (105/121) of stroke patients with
complete recanalisation had a falling LMR compared
with 81% (25/31) in those with incomplete or no recana-
lisation (χ2 = 0.7; p = 0.38).
Fig. 3 Correlation between NLR (a and b), LMR (c and d) and outcome
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Correlation between NLR or LMR and the ischaemic area
as identified using the NIHSS
There was neither significant correlation between a_
NLR or a_LMR and infarct size, nor between NLR or
LMR and sICH, baseline NIHSS score or recanalisation
on univariate analysis. However, higher 24h_NLR and
lower 24h_LMR were associated with larger infarct size,
r = 0.25, p = 0.008 and r = − 0.18, p = 0.05, respectively on
univariate analysis (Fig. 2).
NLR and LMR measured after the procedure were more
correlated with long-term outcome
Higher a_NLR and 24h_NLR were associated with out-
come as measured by 3-month mRS with there being
poorer outcome on univariate analysis, r = 0.27, p = 0.055
and r = 0.47, p < 0.0001, respectively (Fig. 3a, b).
In a similar fashion, the a_LMR and 24h_LMR were
associated with poorer outcome on univariate analysis
but unlike the NLR, it was lower LMR that correlated,
r = − 0.2, p = 0.01 and r = − 0.4, p < 0.0001, respectively
(Fig. 3c, d).
NLR and LMR association with an infarct size on
multivariate logistic regression
The association noted above between 24h_NLR or
24h_LMR and infarct size weakened after age, baseline
NIHSS, presence of good collateral supply, recanalisa-
tion and sICH adjustment on multivariate logistic re-
gression (OR 0.011, 95% Cl − 0.002‑0.024, p = 0.099
and OR 0.018, 95% Cl − 0.067‑0.103, p = 0.674, respect-
ively) (Additional file 1: Table S1).
24h_NLR and 24h_LMR association with poor outcome on
multivariate logistic regression
Higher 24h_NLR as a continuous variable remained a
significant predictor of poor outcome with an adjusted
odds ratio (OR) of 0.022 (95% CI 0.009–0.34, p = 0.001)
whereas the association between a_NLR and outcome
noted above weakened (p = 0.059) when controlling for
age, baseline NIHSS, infarct size, presence of good col-
lateral supply, recanalisation and sICH on multivariate
logistic regression (Additional file 1: Table S2). In this
model, incomplete or absent recanalisation (mTICI 0–
2a) was also significantly associated with poor outcome
(OR 0.207, 95% CI 0.014–0.399, p = 0.036).
Similarly, lower values of 24h_LMR were strongly as-
sociated with poor outcome (adjusted OR − 0.093, 95%
CI (− 0.175)−(− 0.012), p = 0.025) in contrast to the weak
association between a_LMR (noted above) and outcome
(p = 0.3) when controlling for age, baseline NIHSS, infarct
size, presence of good collateral supply, recanalisation and
sICH on multivariate logistic regression (Additional file 1:
Table S3).
24h_NLR and 24h_LMR cut-off points distinguishing poor
outcome
Receiver operating characteristic (ROC) curves were
used to test the overall discriminative ability of the
24h_NLR and 24h_LMR for outcome and to establish
optimal cut-off points at which the sum of the speci-
ficity and sensitivity was highest. The optimal cut-off
values of the NLR and LMR that best discriminated
poor outcome were 5.5 (80% sensitivity and 60% spe-
cificity) and 2.0 (80% sensitivity and 50% specificity)
24 h after MT respectively (Fig. 4).
The patients with high 24h_NLR were older (59.8 ±
10.5 vs 69.6 ± 12.5 years, p = 0.001) and had a higher
proportion of atrial fibrillation (22 vs 44%, p = 0.01)
(Table 1).
Fig. 4 NLR (a) and LMR (b) receiver operating characteristic curve analysis
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In contrast, the patients with low 24h_LMR were
younger (72 ± 1.5 vs 57 ± 12.5, p < 0.0001), had a higher
proportion of hypertension (36 vs 62%, p = 0.006), a
higher baseline NIHSS score (17 vs 19, p = 0.026) and a
poorer baseline mRS (6 vs 20%, p = 0.046) (Table 2).
Discussion
Our study shows that a higher NLR and lower LMR
tested 24 h after MT were independent predictors of 3-
month poor functional outcome after MT for acute
anterior circulation large vessel occlusion stroke.
Table 1 Comparisons of baseline characteristics and outcomes between 24h_NLR groups
Characteristicsa NLR < 5.5 (n = 41) NLR ≥ 5.5 (n = 72) p value
Age, years (SD) 59.8 (10.5) 69.6 (12.5) p = 0.001
Female, No. (%) 19 (46) 39 (54) p = 0.39
Hypertension, No. (%) 17 (41) 41 (57) p = 0.11
High cholesterol, No. (%) 10 (24) 23 (32) p = 0.39
Ischaemic heart disease, No. (%) 2 (5) 9 (13) p = 0.18
Congestive heart failure, No. (%) 1 (2) 9 (13) p = 0.07
Atrial fibrillationb, No. (%) 9 (22) 32 (44) p = 0.01
History of stroke/TIA, No. (%) 10 (24) 13 (18) p = 0.42
Smoking, No. (%) 13 (32) 18 (25) p = 0.44
Baseline NIHSS score, mean (range) 18 (4–27) 19 (2–28) p = 0.121
Baseline mRS ≥ 1, No. (%) 9 (22) 17 (24) p = 0.84
Intravenous thrombolysis, No (%) 34 (83) 55 (76) p = 0.41
mTICI 2b/3, No (%) 35 (85) 50 (69) p = 0.059
sICH, No (%) 1 (2) 8 (11) p = 0.101
mRS at 3 months, mean (range) 2 (0–6) 4 (0–6) p < 0.0001
mRS modified Rankin Scale, NIHSS National Institutes of Health Stroke Scale, 24h_NLR neutrophil-lymphocyte ratio at 24 h after mechanical thrombectomy, No
number, TIA transient ischaemic attack, mTICI modified thrombolysis in cerebral infarction, sICH symptomatic intracranial haemorrhage
a8 cases excluded with missing 24h_NLR data not included, 113 cases included
bAtrial fibrillation diagnosed from an admission 12 lead ECG
Table 2 Comparisons of baseline characteristics and outcomes between 24h_LMR groups
Characteristicsa LMR < 2.0 (n = 68) LMR≥ 2.0 (n = 45) p value
Age, years (SD) 57 (12.5) 72 (1.5) p < 0.0001
Female, No. (%) 34 (50) 24 (53) p = 0.72
Hypertension, No. (%) 42 (62) 16 (36) p = 0.006
High cholesterol, No. (%) 22 (32) 11 (24) p = 0.36
Ischaemic heart disease, No. (%) 8 (12) 3 (7) p = 0.37
Congestive heart failure, No. (%) 8 (12) 2 (4) p = 0.17
Atrial fibrillationb, No. (%) 29 (43) 12 (27) p = 0.08
History of stroke/TIA, No. (%) 14 (21) 9 (20) p = 0.93
Smoking, No. (%) 16 (24) 15 (33) p = 0.25
Baseline NIHSS score, mean (range) 19 (2–28) 17 (4–25) p = 0.026
Baseline mRS ≥ 1, No. (%) 20 (29) 6 (13) p = 0.046
Intravenous thrombolysis, No (%) 54 (79) 35 (78) p = 0.83
mTICI 2b/3, No (%) 47 (69) 38 (84) p = 0.06
sICH, No (%) 8 (12) 1 (2) p = 0.06
mRS at 3 months, mean (range) 4 (0–6) 2.5 (0–6) p = 0.0003
mRS modified Rankin Scale, NIHSS National Institutes of Health Stroke Scale, 24h_LMR lymphocyte-monocyte ratio at 24 h after mechanical thrombectomy, No
number, TIA transient ischaemic attack, mTICI modified thrombolysis in cerebral infarction, sICH symptomatic intracranial haemorrhage
a8 cases excluded with missing 24h_LMR data not included, 113 cases included
bAtrial fibrillation diagnosed from an admission 12 lead ECG
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NLR is a composite marker of absolute peripheral neu-
trophil and lymphocyte counts, and LMR is a composite
marker of absolute peripheral lymphocyte and mono-
cytes counts. These cells comprise the total leukocyte
count which has previously been shown to be associated
with cardiovascular and cancer mortality, as well as all-
cause mortality [17–22]. However, they play a different
role in the inflammation and possibly in the pathogen-
esis of these differing medical conditions. For instance,
high neutrophil counts have been associated with ad-
verse prognosis, whereas high lymphocyte counts have
been considered to have protective effects on survival in
cardiovascular patients [23–25]. While analysing them
together may not highlight the opposing roles they seem
to have, analysing them apart may miss the interaction
between these subtypes and their association with differ-
ent medical conditions. Indeed, among patients with
acute myocardial infarction, it has been shown that an
increased NLR is a predictor of in-hospital mortality and
morbidity [26], and impaired myocardial perfusion after
percutaneous coronary angioplasty [27]. Similarly, LMR
has been reported to be associated with adverse progno-
sis in multiple malignancies [22, 28] and coronary artery
disease [21, 29].
High admission NLR has been found to predict func-
tional independence or death independent of age, treat-
ment with IV rtPA and recanalisation [4]. Interestingly,
baseline or admission NLR or LMR had no independent
predictive value for outcome in our cohort presumably
because the thrombectomy treatment modified the out-
come. Intraparenchymal perivascular neutrophil migra-
tion occurs within 6 to 24 h [30, 31], and further
accumulation of neutrophils in ischaemic and reperfused
areas occurs at a higher rate after endovascular recanali-
sation and correlates with poor neurological outcome
and brain damage severity both in humans and rodents
[32]. Therefore, dynamic measurement of NLR or LMR
may be a stronger predictive tool for outcome compared
with single measurements. Higher NLR within 3 days
after the stroke onset was previously associated with un-
favourable functional outcome at discharge [33]. To our
knowledge, dynamic NLR was not previously assessed in
stroke patients treated with MT.
Previous studies suggested that the initial NLR was asso-
ciated with mortality and infarct size in ischaemic stroke
patients [34, 35]. However, there was no independent asso-
ciation between 24h_NLR or 24h_LMR and infarct size in
our cohort. This may be related to evaluation of the post
procedure CT scan performed in our study. Diffusion-
weighted imaging measures performed after endovascular
treatment were not included into our analysis. Previous
studies reported a correlation between stroke severity and
NLR determined at admission [36, 37]. We could not
confirm these findings. Compared with previous studies
[38, 39], we did not find association between NLR and
sICH in spite of higher rate of sICH in our cohort.
Lower LMR after AIS has been associated with worse
outcomes [40, 41]. The cut-off value of LMR that pre-
dicted poorer outcome in our cohort was lower com-
pared with the previous studies (< 2.0 vs > 2.99) [10, 41].
LMR was previously assessed in AIS patients treated
with thrombolytic therapy [10] but not in relation with
endovascular cerebral treatment. In our cohort, lower
LMR tested 24 h after MT was an independent predictor
of 3-month poor functional outcome after MT for acute
anterior circulation large vessel occlusion stroke inde-
pendent of sICH.
Post-stroke inflammation has a dual role in ischaemic
stroke. Peripheral immune cells are activated after
stroke and may in turn influence the fate of ischaemic
brain tissue [42]. Neutrophils respond early after stroke
and indicate an active inflammatory reaction, while
lymphocytes may have a regulatory function in inflam-
mation inducing neuroprotection [42]. There is evi-
dence that neutrophilia may provoke poor functional
outcome in patients with good collaterals achieving
successful reperfusion after MT. [43] Therefore, reduc-
tion of neutrophils and induction of lymphocyte after
MT may improve functional outcome of AIS after MT.
Our data should be interpreted with some caution due
to limitations of the study. These include retrospective
bias inherent to the study design and a small sample
size.
Conclusion
This study suggests that NLR and LMR tested at 24 h after
endovascular recanalisation therapy may reliably predict
3-month functional outcome. Based on our findings and
previous studies, NLR and LMR may have utility as an in-
clusion criterion for future endovascular therapy clinical
trials, and also suggest further exploration on modulating
immune response to treat AIS.
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